Antitrust attorneys say that a Democratic presidential administration led by President-elect Joe Biden is expected to bring a new intensity to the antitrust space—one that may bleed over into the plaintiffs bar as well.Credit: Roberto Jiménez/ALM; Shutterstock.com
Companies should expect more focused attention and stringent vetting in areas ranging from vertical mergers to pharmaceutical transactions, especially from the U.S. Department of Justice, which, more so than the Federal Trade Commission, has been relatively lax under the Trump administration, antitrust attorneys say.
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]